L-Tyrosine Side Effects

Reported L-Tyrosine side effects

L-Tyrosine has a highly favorable safety profile as a non-essential dietary amino acid that is normally consumed in gram quantities daily from food. Supplemental tyrosine at typical cognitive-performance doses of 500-2000 mg (or even the higher research doses of 7-12 g) produces minimal side effects in healthy users. The compound is generally recognized as safe (GRAS) by regulatory agencies and has been used safely in clinical research for decades. Most common side effects, which occur infrequently and are usually mild: gastrointestinal effects including mild nausea, stomach discomfort, or loose stools at higher doses, particularly on an empty stomach where tyrosine is recommended for optimal BBB transport. Taking tyrosine with a small amount of food (a few carbohydrate grams is acceptable and does not meaningfully interfere with transport) can mitigate GI effects for sensitive users. Mild headache occurs in some users, usually at higher doses or with chronic daily use, typically resolving with dose reduction or cycling. Nervousness, jitteriness, or mild anxiety can occur in sensitive users, reflecting the catecholamine-enhancing mechanism. These effects are more pronounced with combination with caffeine, modafinil, or other stimulants and usually respond to dose reduction. Sleep disturbance can occur if tyrosine is taken late in the day. Morning or early afternoon dosing is recommended; afternoon and evening dosing should be avoided in users sensitive to sleep effects. Cardiovascular effects including mild increases in heart rate and blood pressure can occur at higher doses, particularly in combination with other catecholaminergic or stimulant compounds. These effects are generally clinically insignificant in healthy users but warrant caution in users with hypertension, cardiac arrhythmias, or other cardiovascular conditions. Thyroid function effects are an important theoretical consideration. Tyrosine is a substrate for thyroid hormone synthesis, and high-dose chronic tyrosine supplementation could theoretically increase thyroid hormone production in individuals with hyperthyroidism or borderline thyroid function. In practice, this effect is modest for typical supplementation doses (500-2000 mg daily) in healthy users with normal thyroid function, but users with hyperthyroidism, Graves' disease, or thyroid nodules should consult their physician before starting tyrosine supplementation. Users on thyroid hormone replacement (levothyroxine) for hypothyroidism may experience modest changes in thyroid requirements with chronic tyrosine use, though clinically significant effects are uncommon at typical doses. Melanin synthesis effects are a specific consideration for users with melanoma history or risk factors. Tyrosine is the starting material for melanin biosynthesis via the tyrosinase enzyme in melanocytes. Theoretical concerns exist that high-dose chronic tyrosine supplementation could stimulate melanoma cell growth or promote melanin-related pathology in susceptible individuals. The evidence base for this concern is limited — no clinical studies have demonstrated that dietary or supplemental tyrosine promotes melanoma growth in humans — but users with active melanoma, personal history of melanoma, or strong family history of melanoma should avoid high-dose chronic tyrosine supplementation and should consult their oncologist before starting the compound. MAO inhibitor interactions are a more clearly documented and serious safety concern. Tyrosine is a precursor to catecholamines, and MAO inhibitors prevent the breakdown of catecholamines. The combination of tyrosine supplementation with MAO inhibitor therapy could theoretically produce dangerous elevations in catecholamine levels, resulting in hypertensive crisis, cardiac arrhythmias, or other sympathomimetic toxicity. Patients on MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid, moclobemide) or recent MAO inhibitor use (within 2 weeks of discontinuation) should avoid tyrosine supplementation. This interaction is analogous to the classical "tyramine reaction" that MAO inhibitor patients must avoid with aged cheeses, fermented foods, and certain medications. Interactions with L-DOPA in Parkinson's disease: tyrosine and L-DOPA compete for LAT1 transport at the blood-brain barrier, and high-dose tyrosine could theoretically interfere with L-DOPA delivery to the brain. PD patients on L-DOPA therapy should avoid high-dose tyrosine supplementation or take it at different times than L-DOPA doses. Thyroid medication interactions, as noted above, may occur with chronic high-dose use. Interactions with stimulants (amphetamines, methylphenidate, caffeine at high doses) can produce additive catecholaminergic effects including anxiety, insomnia, and cardiovascular activation. Combining tyrosine with prescription stimulants warrants medical awareness. Overdose risk with tyrosine is low. Ingestion of large quantities produces GI symptoms, headache, and possible cardiovascular activation but is not typically life-threatening. LD50 in animals is very high (>5 g/kg). Management of overdose is supportive. Pregnancy and lactation: tyrosine is a normal dietary component and supplemental doses within the typical range (500-2000 mg daily) are not known to cause developmental or lactation concerns. Higher doses have not been extensively studied in pregnancy, and pregnant women should consult their physician before starting tyrosine supplementation. Pediatric use: tyrosine is safely used in children with PKU at medically directed doses. Cognitive-performance supplementation in children without specific indications is not recommended without medical supervision. Overall, tyrosine's side effect profile is favorable and compatible with routine supplementation in healthy adults, with clear cautions for specific medical conditions and medication interactions.

When to continue, reduce, or stop L-Tyrosine

L-Tyrosine contraindications

L-Tyrosine has a favorable contraindication profile reflecting its status as a normal dietary amino acid. Absolute contraindications are few: concurrent MAO inhibitor therapy (phenelzine, tranylcypromine, isocarboxazid, moclobemide, and similar) or recent MAO inhibitor discontinuation (within 2 weeks) — this combination can produce dangerous catecholamine elevations with risk of hypertensive crisis, cardiac arrhythmias, or sympathomimetic toxicity; known hypersensitivity to L-tyrosine or supplement components. Significant contraindications: active melanoma or recent melanoma treatment — the theoretical concern about tyrosine-supporting melanin synthesis via tyrosinase, while not extensively documented in clinical studies, is sufficient basis to avoid high-dose chronic tyrosine in patients with active melanoma. Patients with strong personal or family history of melanoma should consult their oncologist or dermatologist before starting L-tyrosine supplementation. Hyperthyroidism and Graves' disease: tyrosine is a substrate for thyroid hormone synthesis, and chronic supplementation could theoretically worsen hyperthyroid states. Patients with hyperthyroidism, treated Graves' disease, or thyroid nodules under evaluation should avoid or use L-tyrosine only with endocrinology oversight. Relative contraindications and precautions: hypertension — tyrosine's catecholaminergic effects can modestly increase blood pressure; patients with uncontrolled hypertension should avoid L-tyrosine or use low doses with close BP monitoring; patients with controlled hypertension can usually use L-tyrosine but should monitor BP trends. Cardiovascular disease (recent MI, unstable angina, arrhythmias): similar considerations; use only with cardiology oversight if at all. Parkinson's disease on L-DOPA therapy: tyrosine and L-DOPA compete for BBB LAT1 transport; dosing at different times than L-DOPA (3-4 hours separation) may minimize interference but the combination is generally not ideal. Phenylketonuria (PKU): patients with PKU cannot convert phenylalanine to tyrosine effectively, and supplemental tyrosine is actually part of their medical management rather than a concern — this is an indication rather than a contraindication. Pregnancy: tyrosine is a normal dietary component and supplemental doses within the typical range (500-2000 mg daily) are not expected to cause pregnancy complications. Higher doses have not been extensively studied in pregnancy. Pregnant women should consult their physician before starting L-tyrosine supplementation. Breastfeeding: similar to pregnancy — normal dietary ranges are not concerning; higher doses should be discussed with the physician. Pediatric use: safe in children with PKU at medically directed doses. Cognitive performance supplementation in healthy children should be avoided without specific medical guidance. Psychiatric disorders: bipolar disorder may theoretically be worsened by catecholaminergic activation, though clinically significant effects at typical supplement doses are uncommon. Patients with bipolar disorder should discuss L-tyrosine with their psychiatrist before use. Schizophrenia: dopaminergic activation is generally contraindicated in active psychosis; patients with schizophrenia or schizoaffective disorder should not use L-tyrosine outside of psychiatric supervision. Anxiety disorders: may be worsened by tyrosine's activating effects; users with significant anxiety should test with caution or avoid. Renal impairment: tyrosine is not primarily renally cleared and does not accumulate significantly in renal impairment. Dose adjustment is not typically required but common sense suggests avoiding chronic high doses in advanced kidney disease. Hepatic impairment: tyrosine metabolism is primarily enzymatic at sites of catecholamine synthesis rather than hepatic; significant hepatic impairment does not require dose adjustment. Drug interactions of clinical concern: MAO inhibitors (absolute avoidance — the most important drug interaction); amphetamines and methylphenidate (theoretical additive catecholamine effects; coordinate with prescriber); SSRIs and SNRIs (generally compatible; some stack designers use tyrosine as adjunctive support); L-DOPA (timing separation to avoid LAT1 competition); thyroid hormone replacement (possible modest effects on thyroid requirements over time, monitor TSH); cardiovascular medications (additive blood pressure effects possible in some combinations); other catecholaminergic compounds (additive effects). Compounds that are generally compatible: caffeine, L-theanine, modafinil (with monitoring), piracetam, noopept, sulbutiamine, omega-3 fatty acids, B-complex vitamins, magnesium, most supplements and prescription medications not in the above categories. Absence of clinical oversight is the general consideration. For healthy adults using L-tyrosine within the typical supplement dose range for cognitive performance, formal medical oversight is not strictly required. For users with specific medical conditions, significant medication regimens, or higher doses, medical involvement is appropriate. Users should inform their physicians of L-tyrosine use during routine healthcare encounters to ensure appropriate consideration in clinical decision-making.

Why vendor quality drives L-Tyrosine side-effect frequency

Research-compound communities consistently report that adverse-event frequency tracks with source quality. Three reasons: (1) impurity profiles vary by lab (residual synthesis byproducts can trigger reactions); (2) mislabeled mass means actual dose can be 50-150% of stated dose; (3) reconstitution-grade water and capping methodology affect long-term storage stability. COA-verified vendors with published HPLC data minimize all three failure modes. Check a vendor's COA record and Trust Score before you buy.

L-Tyrosine side effects FAQ

Research-use disclaimer. All safety information on this page summarizes published research literature and community-reported reactions. It is not medical advice and not authorization for human consumption. Always consult a licensed practitioner before any compound enters a clinical context. Compounds linked from this page are sold for research-use only.
Affiliate disclosure. See our affiliate disclosure .